Iterum Therapeutics (ITRM) Non Operating Income (2017 - 2022)
Historic Non Operating Income for Iterum Therapeutics (ITRM) over the last 6 years, with Q4 2022 value amounting to $2.9 million.
- Iterum Therapeutics' Non Operating Income rose 422.29% to $2.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$13.8 million, marking a year-over-year increase of 7926.78%. This contributed to the annual value of -$5.8 million for FY2024, which is 16012.36% down from last year.
- According to the latest figures from Q4 2022, Iterum Therapeutics' Non Operating Income is $2.9 million, which was up 422.29% from -$22.6 million recorded in Q3 2022.
- Over the past 5 years, Iterum Therapeutics' Non Operating Income peaked at $14.9 million during Q2 2021, and registered a low of -$93.0 million during Q1 2021.
- In the last 5 years, Iterum Therapeutics' Non Operating Income had a median value of $10500.0 in 2019 and averaged -$5.0 million.
- Its Non Operating Income has fluctuated over the past 5 years, first crashed by 387087.38% in 2020, then soared by 46447.43% in 2021.
- Iterum Therapeutics' Non Operating Income (Quarter) stood at $218000.0 in 2018, then tumbled by 289.91% to -$414000.0 in 2019, then crashed by 1474.4% to -$6.5 million in 2020, then soared by 143.23% to $2.8 million in 2021, then rose by 4.22% to $2.9 million in 2022.
- Its Non Operating Income was $2.9 million in Q4 2022, compared to -$22.6 million in Q3 2022 and $1.7 million in Q2 2022.